carbidopa


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to carbidopa: Entacapone

carbidopa

 [kahr-bĭ-do´pah]
an inhibitor of the decarboxylation of levodopa in peripheral tissues; it does not cross the blood-brain barrier and is used in combination with levodopa to control the symptoms of parkinson's disease. In the presence of carbidopa, levodopa enters the brain in larger quantities, thus avoiding the need for excessively high doses of levodopa.

car·bi·do·pa

(kar'bi-dō'pă),
A dopa decarboxylase inhibitor that does not enter the brain used in conjunction with levodopa in the treatment of Parkinson disease to reduce L-dopa dosage and mitigate side effects.

carbidopa

/car·bi·do·pa/ (kahr″bĭ-do´pah) an inhibitor of decarboxylation of levodopa in extracerebral tissues, used in combination with levodopa as an antiparkinsonian agent.

carbidopa

(kär′bĭ-dō′pə)
n.
A drug, C10H14N2O4, that increases the availability of L-dopa to the brain and is administered with L-dopa to treat Parkinson's disease.

carbidopa

[kär′bidō′pə]
a dopa decarboxylase inhibitor that cannot cross the blood-brain barrier.
indication It is prescribed in combination with levodopa in the treatment of idiopathic Parkinson's disease because it inhibits the degradation of levodopa in the periphery, thereby permitting a larger percentage of orally administrated doses to enter the brain.
contraindications Glaucoma, hypertension, use of a monoamine oxidase inhibitor within the past 14 days, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the most serious adverse reactions are GI bleeding, cardiac irregularity, hemolytic anemia, tardive dyskinesia, mental depression, blurred vision, and activation of malignant melanoma.

car·bi·do·pa

(kahr'bi-dō'pă)
A dopa decarboxylase inhibitor that does not enter the brain used in conjunction with levodopa in the treatment of parkinsonism to reduce L-dopa dosage and mitigate side effects.

carbidopa

A drug that prevents the breakdown of the drug levodopa in the body and thus enhances its action in PARKINSON'S DISEASE. See also BENSERAZIDE. A brand name is Sinemet.

carbidopa

formulation of dopamine, used to control symptoms of Parkinson's disease
References in periodicals archive ?
Carbidopa then lowers the amount of levodopa that is required by the body and can reduce some of the side-effects of levodopa, like nausea and vomiting.
In a paper (containing 90 scientific references) published in Clinical Pharmacology, Hinz, Alvin Stein, and Ted Cole note that the only indication for carbidopa and benserazide is the management of L-dopa-induced nausea.
Mohaddesi pointed out to another finding in this research, and said, "The use of carbon nanotube showed desirable results in the measurement of carbidopa at very low concentrations.
The unique design of this trial should allow us to not only explore the role and potential therapeutic application of norepinephrine in fibromyalgia, but, by pairing droxidopa with carbidopa to limit peripheral metabolism of droxidopa into norepinephrine, should also allow us to more closely examine the central effect of NE in this indication.
CHF1512 (to be known in the future as GT1512) is a combination containing two known drug substances: melevodopa hydrochloride, a levodopa pro-drug (LDME), and carbidopa and was developed by Chiesi Farmaceutici of Parma, Italy.
Stalevo (levodopa, carbidopa and entacapone) is a new and optimized levodopa product with a longer duration of action compared to traditional levodopa/carbidopa preparations.
Stalevo (levodopa, carbidopa and entacapone) is a new and optimised levodopa product with a longer duration of action compared to traditional levodopa/carbidopa preparations.
28,34] The practice of withholding levodopa/ carbidopa has recently been addressed by a consensus group.
The preliminary results indicate that the bi-layer tablet formulation provided a sustained levodopa exposure that was consistent with XenoPort's prior open-label trial that utilized separate extended-release XP21279 and commercially-available carbidopa tablets.
About DUOPA (carbidopa and levodopa) enteral suspension DUOPA is a new approach to the administration of carbidopa and levodopa for the treatment of motor fluctuations for people with advanced Parkinson's disease.
Clinical deterioration of the motor symptoms of Parkinson's disease did not occur in 81 patients who received carbidopa and levodopa at 600 mg per day after 42 weeks, according to scores on the Unified Parkinson's Disease Rating Scale.
53003 Levodopa 200 Mg Plus Carbidopa 50 Mg Cr Tablet